since the study period. In-vitro tests of thryoid function have become more specific and more available recently and we believe that these should now be included in the routine investigations whenever there is the slightest suspicion that hyperthyroidism or hypothyroidism might account for a patient's presenting bowel disorder.
A total of 57% of the surviving patients (18 men and 26 women) still had their symptoms at follow up, though most had learnt to live with the problem and confirmed that reassurance and explanation were particularly important in treatment. This confirms the conclusions of previous studies that the irritable bowel syndrome is often a chronic, relapsing disorder4 6 Conversion: SI to traditional units-Sodium: 1 mmol/l= 1 mEq/l.
The variceal haemorrhage stopped without vasopressin. Fluid retention was treated by restricting fluids and sodium and administering spironolactone, up to 200 mg daily. His encephalopathy responded initially to protein restriction and lactulose, but later bromocriptine was added to a final dose of 15 mg daily. Seven weeks later his mental state had deteriorated and he was confused. The serum sodium concentration was 116 mmol/l (figure) with normal blood urea and serum potassium concentrations. Spironolactone was stopped and fluid intake restricted to 500 ml daily, but there was no improvement. Three days later, when the serum sodium concentration was 1 3 mmol/l, urinary sodium excretion 47 mmol/l, and serum and urinary osmolalities 242 and 639 mmol/kg, the bromocriptine was stopped. Within 24 hours urinary sodium excretion was 3 mmol/l and osmolality 234 mmol/kg. Over the next two weeks his clinical condition and electrolyte abnormalities improved; he had a moderate diuresis and lost 2 kg in weight.
The development of hyponatraemia with continued renal excretion of sodium during treatment with bromocriptine suggested inappropriate secretion of antidiuretic hormone. He was restabilised taking 20 mmol sodium and 1 1 fluid daily. Plasma cortisol concentrations were normal. Plasma renin activity was 10-4 nmol/l/h (13-5 ng/ml/h) (normal 0-8-3-5 nmol/ 1/h; 1-0-4-5 ng/ml/h) and plasma aldosterone concentration 13-5 nmol/l (0-49 tig/100 ml) (normal 0-3-1-1 nmol/l; 0-01-0-04 [kg/100 ml), both measured with the patient supine. The rate of urinary excretion of antidiuretic hormone was 144 fmol/min (156 pg/min) (normal 40-90 fmol/min; 43-98 pg/min).
With the patient's consent bromocriptine was reintroduced at a dose of 7-5 mg daily. Within five days the serum sodium concentration had fallen to 118 mmol/l and urinary sodium increased to 21 mmol/l; serum and urinary osmolalities were 268 and 433 mmol/kg. Plasma renin activity (9-2 nmol/l/h; 12-0 ng/ml/h), plasma aldosterone concentration (9 0 nmol/l; 0-33 4g/100 ml) and the rate of urinary excretion of antidiuretic hormone (163 fmol/min; 177 pg/min) did not change appreciably. Bromocriptine was stopped with prompt improvement in the electrolyte abnormalities.
Comment
Hyponatraemia is common in cirrhosis; the mechanism is unclear since total body sodium is often increased. Bromocriptine contributed substantially to the hyponatraemia in this patient, although how it did so is necessarily speculative. Several features suggested that the drug induced inappropriate secretion of antidiuretic hormone. Urinary sodium excretion continued despite profound hyponatraemia, and the urinary osmolality was inappropriately higher than the serum osmolality; the patient was not dehydrated and had normal renal and adrenal function. Pretreatment urinary excretion of antidiuretic hormone was, however, high, a feature often observed in patients with cirrhosis,2 and it did not change substantially when the drug was reintroduced. This does not exclude inappropriate secretion of antidiuretic hormone since plasma concentrations of the hormone were not measured; indeed, bromocriptine stimulates secretion of antidiuretic hormone in normal subjects.3 It may possibly also alter renal responsiveness to circulating antidiuretic hormone; as a result expansion of the circulating fluid volume and secondary natriuresis might follow. Bromocriptine can produce modest natriuresis either from a direct effect on the kidney or because of dopaminergic inhibition of release of aldosterone.4 The latter mechanism is unlikely to have been important in this patient as plasma renin activity and aldosterone concentrations were little affected by bromocriptine. The only case of eclampsia in a renal transplant recipient was reported in 1979 from this unit.' The patient's subsequent pregnancy was not complicated by hypertension and had a normal outcome, as is reported here.
Case report
The patient originally presented in 1973, aged 14 years, with hypertension and the nephrotic syndrome due to mesangiocapillary glomerulonephritis. In 1977 she received a cadaveric renal transplant (with no HLA antigens in common) that functioned well after three rejection episodes.
In 1979 she presented at the antenatal clinic with a 20-week pregnancy. She was normotensive, and the pregnancy progressed uneventfully until 30 weeks, when she developed an acute fulminating hypertensive illness (blood pressure -1977 1978 1979 1980 1981 1982 Serial measurements of plasma creatinine concentration, creatinine clearance, and urine protein excretion after transplantation.
Conversion: SI to traditional units-Plasma creatinine: 1 ,umol/l0001 mg/100 ml.
The patient was advised against further pregnancies but conceived again 17 months later, accepted the risks to her kidney, and continued with the pregnancy, which progressed without complication. Clear liquor drained spontaneously at 37 weeks and was followed by a low forceps delivery of a healthy female infant weighing 3530 g. Renal function remained unimpaired during and after pregnancy, blood pressure did not exceed 145/90 mm Hg, and proteinuria remained less than 0-25 g/day.
Drug treatment consisted of immunosuppression with prednisolone 12-5 mg and azathioprine 150 mg daily. Antihypertensive treatment comprised propranolol 160 mg, hydralazine 50 mg, and bendrofluazide 5 mg daily at the time of the first pregnancy and labetolol 300 mg and hydralazine 50 mg daily at the time of the second pregnancy.
Comment
The occurrence and course of hypertension in pregnancy are unpredictable, and this case exemplifies the difficulty in advising patients about the risks. Incorrect advice had initially been given to this patient. In retrospect, the hypertensive illness in the first pregnancy was classical toxaemia of pregnancy and not complicated renal hypertension, which would be expected to recur in subsequent pregnancies.
The risks of damage to the renal transplant associated with pregnancy are well documented.2 3 Some patients, however, are willing to accept these in the hope of a successful outcome. Eclampsia in the first pregnancy need not be a contraindication to further pregnancies in renal transplant recipients, even in the presence of mild hypertension. The data obtained in the normotensive group were used to construct a "one-tailed" nomogram. At every point of the exercise testing mean systolic blood pressure and diastolic blood pressure+ 1-65 SD were plotted (figure). A normotensive response to exercise was defined as diastolic blood pressure < 90 mm Hg at the baseline reading and at a work load of 6000 N m; a hypertensive response was defined as diastolic blood pressure >95 mm Hg at the baseline reading and >95 mm Hg at a work load of 6000 N m ( figure) .
Systolic blood pressure in the normotensive subjects was 116±4 mm Hg before exercise, rising to 168±4 mm Hg at 6000 N m. Diastolic pressure was 77±1 mm Hg initially and remained virtually unchanged; after one and five minutes' rest it was 66±2 and 69±2 mm Hg respectively. In the
